Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670184 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5791149 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5790915 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5788771 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL185904 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5792045 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL671072 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5792603 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5042 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL669339 | 1.00 | PDE4A (0.50) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3620510-B2 | FERMENTATIVE PRODUCTION OF OLIGOSACCHARIDES BY TOTAL FERMENTATION UTILIZING A MIXED FEEDSTOCK | CHR HANSEN HMO GMBH (DE) | 2026-05-27 | — | — | EP | claimed |
| CN-122071711-A | Platycodon phosphomannose mutase gene PgPMM, coded product and application thereof | 安徽中医药大学 | 2026-05-22 | — | — | CN | claimed |
| US-20260015376-A1 | CONTINUOUS FLOW METHODS FOR PRODUCING MANNOSE-1-PHOSPHATE, POLYMORPHS OF MANNOSE-1-PHOSPHATE, AND COMPOSITIONS AND USES RELATED THERETO | GLYCOMINE, INC. (US) | 2026-01-15 | — | — | US | claimed |
| US-12338473-B2 | Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock | CHR. HANSEN A/S (DK) | 2025-06-24 | — | — | US | claimed |
| US-20250186345-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2025-06-12 | — | — | US | claimed |
| EP-4526461-A1 | BIOMANUFACTURING OF OLIGOSACCHARIDES AND DERIVATIVES FROM SIMPLE SUGARS | ZYMtronix Catalytic Systems, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119570647-A | Genetically engineered bacterium for producing 2' -fucosyllactose based on mannitol, construction method and application thereof | 山东大学 | 2025-03-07 | — | — | CN | claimed |
| CN-119546773-A | Biological production of oligosaccharides and derivatives from monosaccharides | 齐姆特罗尼克斯催化系统股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| EP-3954360-B1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE INC (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2025029879-A1 | ASSESSING AND TREATING MAMMALS HAVING METABOLIC DISORDERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-02-06 | — | — | WO | claimed |
| EP-1045916-A1 | ENZYMATIC CONVERSION OF GDP-MANNOSE TO GDP-FUCOSE | CYTEL CORPORATION (US) | 2000-10-25 | — | — | EP | claimed |
| EP-0728006-B1 | USE OF MANNOSE PHOSPHATES FOR THE TREATMENT OF FIBROTIC DISORDERS | BTG INT LTD (GB) | 2000-10-11 | — | — | EP | claimed |
| EP-0576592-B1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999036555-A1 | ENZYMATIC CONVERSION OF GDP-MANNOSE TO GDP-FUCOSE | CYTEL CORPORATION (US) | 1999-07-22 | — | — | WO | claimed |
| EP-0642526-B1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | SCRIPPS RESEARCH INST (US) | 1998-12-23 | — | — | EP | claimed |
| EP-0642526-A4 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE. | SCRIPPS RESEARCH INST (US) | 1996-04-10 | — | — | EP | claimed |
| WO-1995024497-A2 | ENZYMATIC PREPARATION OF POLYSACCHARIDES | FIDIA ADVANCED BIOPOLYMERS S.R.L. (IT) | 1995-09-14 | — | — | WO | claimed |
| EP-0642526-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1994001448-A1 | OLIGONUCLEOTIDES MODIFIED WITH CONJUGATE GROUPS | PHARMAGENICS, INC. (US) | 1994-01-20 | — | — | WO | claimed |
| WO-1993008205-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015376-A1 | CONTINUOUS FLOW METHODS FOR PRODUCING MANNOSE-1-PHOSPHATE, POLYMORPHS OF MANNOSE-1-PHOSPHATE, AND COMPOSITIONS AND USES RELATED THERETO | MAN2A1, M6PR, MPI | PDE4A 816/4885LMNA 1775/4885L3MBTL1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.